Am J Health Syst Pharm. 2006;63(17):1641-1646. Our institution, the University of Virginia Health System (UVHS), added factor VIIa (recombinant) to its formulary on August 27, 1999. Informal ...
Purpose. Unlabeled uses of factor VIIa (recombinant) in pediatric patients are reviewed. Summary. Factor VIIa (recombinant) is currently approved for the treatment and prevention of bleeding in ...
can be bypassed by administration of recombinant Factor VIIa. However, the short half-life of recombinant Factor VIIa in vivo negates its routine clinical use. We report here an in vivo method for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback